Media & Publications


iHealthScreen Receives U.S. FDA 510(k) Clearance (K253704) for iPredict-DR, an AI-Powered Software for Automated Diabetic Retinopathy Screening

iHealthScreen announced it has received U.S. FDA 510(k) clearance for iPredict-DR, an AI-powered software for automated diabetic retinopathy screening. The tool detects diabetic retinopathy from retinal images, addressing a significant healthcare gap by enabling screening in primary care settings where patients often lack access to eye care specialists. The company plans to pursue additional FDA clearances for detecting age-related macular degeneration, glaucoma, and cardiovascular disease risk. […]

Continue Reading

iHealthScreen Seeks FDA Approval for AI-Powered AMD Tool

iHealthScreen, in a groundbreaking move, has successfully submitted for FDA 510(k) clearance for iPredict, positioning itself as the first-ever company to seek FDA approval for screening Age-Related Macular Degeneration (AMD), as stated in an official news release.[…]

Continue Reading

iHealthScreen Announces FDA 510(k) Submission for iPredict Automated AI-Based AMD Tool

iHealthScreen has submitted for FDA 510(k) clearance for iPredict, making it the first company to apply for an FDA clearance for screening AMD, according to a company news release. iPredict AI Eye Screening System provides fully automated age-related macular degeneration (AMD) screening, including retinal imaging and immediate reporting of actionable results. Using the iPredict System, primary care and various specialty practices can accurately and efficiently screen people over 50 for AMD and refer them to a specialist (i.e., an ophthalmologist), according to iHealthScreen. […]

Continue Reading

iHealthScreen Inc. Announces FDA 510K Submission for iPredict™ AMD tool – An Automated AI-based Software as a Medical Device for Early Diagnosis of Age-Related Macular Degeneration (AMD)

iHealthScreen is the first company to apply for an FDA 510K clearance for screening AMD, which is a leading cause of blindness in the developed world. NEW YORK, May 23, 2023--(BUSINESS WIRE)--iPredictTM AI Eye Screening System provides fully automated age-related macular degeneration (AMD) screening, including retinal imaging and immediate reporting of actionable results. Using the iPredictTM System, primary care and various specialty practices can accurately and efficiently screen people over 50 for AMD and refer them to a specialist (i.e., an ophthalmologist). […]

Continue Reading

SUBSPECIALTY NEWS: FDA approves Cimerli, GATHER2 GA trial meets primary endpoint, and more.

Coherus Biosciences announced that the FDA has approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab; Genentech), for all 5 indications: wet AMD, macular edema following RVO, DME, DR, and myopic choroidal neovascularization, meeting the FDA's standards to the reference product, including safety, efficacy and quality. Commercial availability of Cimerli, in both 0.3 mg and 0.5 mg dosages, is planned for October 2022. […]

Continue Reading

Artificial Intelligence as a Disruptor to AMD Diagnosis

Not long from now, patients may come to you with a referral from an artificial intelligence (AI) system. The patient will bring — or perhaps send — images taken by a technician at a drug store with the guidance of another AI. You will use a third AI to plan these patients' treatments for age-related macular degeneration (AMD). […]

Continue Reading

Early Diagnosis of Diabetic Retinopathy | Bloomberg vouch report

Bloomberg Published – iHealthScreen Inc. Announces CE Certification for iPredictTM Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR) iHealthScreen Inc. Announces CE Certification for iPredictTM Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age Related Macular degeneration (AMD), and Glaucoma Suspect iHealthScreen is the first company in the USA to receive […]

Continue Reading

iHealthScreen inc has started providing services in Bangladesh as iHealthScreen Bangladesh Ltd

iHealthScreen inc has started providing services in Bangladesh as iHealthScreen Bangladesh Ltd iHealthScreen Bangladesh Ltd, a local healthcare service provider, in collaboration with the Diabetic Association of Bangladesh (DAB), launched its artificial health screening services in the country on Saturday. The services will help prevent diabetic patients from becoming blind and can give information in […]

Continue Reading

Artificial eye health screening starts countrywide

Bangladesh Diabetic Samity Secretary General Md Sayef Uddin along with others attend the inaugural ceremony of artificial eye health screening activities at Sufia Kamal Auditorium of the National Museum in the capital's Shahbagh on Sunday. —SUN photo Artificial eye health screening activities kicked off across the country on Sunday, aiming to protect people against eye […]

Continue Reading

AI Model Predicts Risk for Age-Related Macular Degeneration

WEDNESDAY, May 27, 2020 (HealthDay News) — A new artificial intelligence algorithm can predict the risk for age-related macular degeneration (AMD), according to a study published in the April issue of Translational Vision Science and Technology. Alauddin Bhuiyan, Ph.D., from iHealthScreen Inc. in New York City, and colleagues used 116,875 color fundus photos from 4,139 […]

Continue Reading

BADAS agreement for 5M patients screening

An agreement has been signed and handing over the contract between Innovation Place Bangladesh (IPB) and Diabetic Association of Bangladesh (BADAS) for automated diabetic retinopathy screening services recently. According to the agreement, IPB will examine the diabetic retinopathy (DR) of about 50 lakh diabetic patients registered in Bangladesh Diabetes Association. From Left: Md Saifuddin (Secretary […]

Continue Reading

Recent Post

iHealthScreen Receives U.S. FDA 510(k) Clearance (K253704) for iPredict-DR, an AI-Powered Software for Automated Diabetic Retinopathy Screening

iHealthScreen announced it has received U.S. FDA 510(k) clearance for iPredict-DR, an AI-powered software for automated diabetic retinopathy screening. The tool detects diabetic retinopathy from retinal images, addressing a significant healthcare gap by enabling screening in primary care settings where patients often lack access to eye care specialists. The company plans to pursue additional FDA clearances for detecting age-related macular degeneration, glaucoma, and cardiovascular disease risk. […]

iHealthScreen Seeks FDA Approval for AI-Powered AMD Tool

iHealthScreen, in a groundbreaking move, has successfully submitted for FDA 510(k) clearance for iPredict, positioning itself as the first-ever company to seek FDA approval for screening Age-Related Macular Degeneration (AMD), as stated in an official news release.[…]

iHealthScreen Announces FDA 510(k) Submission for iPredict Automated AI-Based AMD Tool

iHealthScreen has submitted for FDA 510(k) clearance for iPredict, making it the first company to apply for an FDA clearance for screening AMD, according to a company news release. iPredict AI Eye Screening System provides fully automated age-related macular degeneration (AMD) screening, including retinal imaging and immediate reporting of actionable results. Using the iPredict System, primary care and various specialty practices can accurately and efficiently screen people over 50 for AMD and refer them to a specialist (i.e., an ophthalmologist), according to iHealthScreen. […]

iHealthScreen Inc. Announces FDA 510K Submission for iPredict™ AMD tool – An Automated AI-based Software as a Medical Device for Early Diagnosis of Age-Related Macular Degeneration (AMD)

iHealthScreen is the first company to apply for an FDA 510K clearance for screening AMD, which is a leading cause of blindness in the developed world. NEW YORK, May 23, 2023--(BUSINESS WIRE)--iPredictTM AI Eye Screening System provides fully automated age-related macular degeneration (AMD) screening, including retinal imaging and immediate reporting of actionable results. Using the iPredictTM System, primary care and various specialty practices can accurately and efficiently screen people over 50 for AMD and refer them to a specialist (i.e., an ophthalmologist). […]

SUBSPECIALTY NEWS: FDA approves Cimerli, GATHER2 GA trial meets primary endpoint, and more.

Coherus Biosciences announced that the FDA has approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab; Genentech), for all 5 indications: wet AMD, macular edema following RVO, DME, DR, and myopic choroidal neovascularization, meeting the FDA's standards to the reference product, including safety, efficacy and quality. Commercial availability of Cimerli, in both 0.3 mg and 0.5 mg dosages, is planned for October 2022. […]

Artificial Intelligence as a Disruptor to AMD Diagnosis

Not long from now, patients may come to you with a referral from an artificial intelligence (AI) system. The patient will bring — or perhaps send — images taken by a technician at a drug store with the guidance of another AI. You will use a third AI to plan these patients' treatments for age-related macular degeneration (AMD). […]

Early Diagnosis of Diabetic Retinopathy | Bloomberg vouch report

Bloomberg Published – iHealthScreen Inc. Announces CE Certification for iPredictTM Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR) iHealthScreen Inc. Announces CE Certification for iPredictTM Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age Related Macular degeneration (AMD), and Glaucoma Suspect iHealthScreen is the first company in the USA to receive […]

iHealthScreen inc has started providing services in Bangladesh as iHealthScreen Bangladesh Ltd

iHealthScreen inc has started providing services in Bangladesh as iHealthScreen Bangladesh Ltd iHealthScreen Bangladesh Ltd, a local healthcare service provider, in collaboration with the Diabetic Association of Bangladesh (DAB), launched its artificial health screening services in the country on Saturday. The services will help prevent diabetic patients from becoming blind and can give information in […]

Artificial eye health screening starts countrywide

Bangladesh Diabetic Samity Secretary General Md Sayef Uddin along with others attend the inaugural ceremony of artificial eye health screening activities at Sufia Kamal Auditorium of the National Museum in the capital's Shahbagh on Sunday. —SUN photo Artificial eye health screening activities kicked off across the country on Sunday, aiming to protect people against eye […]

AI Model Predicts Risk for Age-Related Macular Degeneration

WEDNESDAY, May 27, 2020 (HealthDay News) — A new artificial intelligence algorithm can predict the risk for age-related macular degeneration (AMD), according to a study published in the April issue of Translational Vision Science and Technology. Alauddin Bhuiyan, Ph.D., from iHealthScreen Inc. in New York City, and colleagues used 116,875 color fundus photos from 4,139 […]

BADAS agreement for 5M patients screening

An agreement has been signed and handing over the contract between Innovation Place Bangladesh (IPB) and Diabetic Association of Bangladesh (BADAS) for automated diabetic retinopathy screening services recently. According to the agreement, IPB will examine the diabetic retinopathy (DR) of about 50 lakh diabetic patients registered in Bangladesh Diabetes Association. From Left: Md Saifuddin (Secretary […]